Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could less radiation be better for head and neck cancer patients?

NCT ID NCT06030440

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving less radiation after surgery for certain head and neck cancers can reduce long-term side effects, like trouble swallowing, without allowing the cancer to come back. About 508 adults who have had surgery and need standard post-op radiation will be randomly assigned to either the usual radiation or a reduced version that skips some neck areas. The goal is to see if the gentler approach leads to fewer feeding tube dependencies and similar cancer control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy
What this could lead to
If successful, this could lead to a new standard of care that reduces long-term side effects like swallowing problems for head and neck cancer patients.
What could go wrong
This is an early-to-mid stage trial, so results are not guaranteed. Reducing radiation might increase the risk of cancer returning in untreated areas.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 508 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Sep 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically proven squamous cell carcinoma of the oral cavity/larynx/oro-or hypopharynx (except glottis cancer (pT1/2pN0)) 2. Surgery of primary tumor and neck dissection performed according to predefined surgical standard 3. Indication for postoperative radio(chemo)therapy 4. No lymph node metastases \> 6cm 5. Lymph node metastases in not more than 3 lymph node level 6. No distant metastases (cM0) 7. Age ≥ 18 years, no upper age limit 8. Eastern Cooperative Oncology Group (ECOG) ≤ 2 9. Patients who understood protocol contents and are able to behave according to protocol 10. Signed study-specific consent form prior to therapy 11. Start of radiotherapy at least 6 weeks after last tumor-specific surgery (e.g. resection primary tumor, neck dissection, excluded are surgeries according to wound healing complications) Exclusion Criteria: 1. macroscopic incomplete resection R2 2. Distant metastases (cM1) 3. Radiologically or histologically proven early recurrence after surgery (time frame from surgery to start of radio(chemo)therapy) 4. Lymph node metastases in \> 3 lymph node level 5. pregnant or lactating/nursing women 6. fertile patients that are not willing to use highly effective methods of contraception (per institutional standards) during treatment 7. Any condition potentially hampering compliance with the study protocol and follow-up schedule 8. On-treatment participation on other clinical therapeutic trials 9. Prior tumor-specific therapy any other than surgery (like prior radiotherapy in the head and neck region, prior chemo- or immunotherapy (neoadjuvant/induction)) 10. Patients who have contraindication for MRI and CT with contrast agent (both) 11. Prior (\> 2 months before beginning of radio(chemo)therapy) neck dissection or surgery in the head and neck area affecting lymph drainage 12. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before diagnosis of head and neck cancer, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ without evidence of disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Squamous cell carcinoma of the hypopharynx are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universitätsklinikum Erlangen, Strahlenklinik

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.